Skip to content

First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.

Nov 2026 · Leukemia and Lymphoma · pp. 1-7 · 0 citations · 8 references
Medicine

TL;DR

A 69-year-old female with newly diagnosed MLNFGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma remains in complete remission at 17 months after pemigatinib initiation, with treatment-related toxicity being manageable through dose modifications and temporary interruptions.

Abstract

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLNFGFR1) are rare, aggressive hematologic malignancies with limited treatment options. Although pemigatinib is approved for relapsed/refractory disease, evidence supporting its role in the frontline setting remains limited. We report a 69-year-old female with newly diagnosed MLNFGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma. As the patient declined intensive chemotherapy, frontline pemigatinib was initiated in combination with intrathecal chemotherapy for central nervous system prophylaxis. A rapid hematologic response was achieved, followed by complete metabolic and cytogenetic responses. At 17 months after pemigatinib initiation, she remains in complete remission, with treatment-related toxicity being manageable through dose modifications and temporary interruptions. This case illustrates the potential of FGFR1 inhibition as a frontline therapeutic option in selected patients with MLNFGFR1, while highlighting the importance of careful toxicity management and the need for further studies to establish its role in this setting.

View source

Similar papers

Review Open access Sep 2026

Relapsed Follicular Lymphoma in 2026: Evolving Treatment Strategies in the Canadian Context

Follicular lymphoma (FL) is the most common indolent lymphoma, characterized by a relapsing-remitting course over many years and repeated need for systemic therapy.1 Although outcomes for many patients are excellent, with median overall survival (OS) now exceeding 20 years, a subset of patients experiences early relaps...

M. Keating · 0 citations
Case report Open access Nov 2026

Futibatinib as a bridge to transplantation and post-transplant maintenance in blast-phase MLN-ZMYM2::FGFR1

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN-FGFR1) are rare, aggressive hematologic malignancies for which allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option. Pemigatinib, a reversible FGFR1-3 inhibitor, has substantial activity in chronic phase but lower...

Tino Vollmer, Christoph Schell, Milena Pantić et al. · 0 citations
Open access Oct 2026

Case Report: Sonrotoclax in combination with azacitidine for acute undifferentiated leukemia

Acute undifferentiated leukemia (AUL) is a rare, highly aggressive hematologic malignancy with a dismal prognosis and no standardized first-line treatment. Conventional acute myeloid leukemia (AML)-type or acute lymphoblastic leukemia (ALL)-type chemotherapy yields low remission rates, and most patients fail to achie...

Cheng Cheng, Rui-Hua Mi, Dong-Bei Li et al. · 0 citations
Review Open access Oct 2026

Advances in CAR-T and CAR-NK cell therapy in follicular lymphoma: a review.

Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma and is characterized by prolonged survival but recurrent relapses. The unmet need is greatest among patients with high-risk disease, including progression of disease within 24 months of first-line immunochemotherapy (POD24), double-refract...

Si-Jia Yan, Wan-Ying Liu, Mi Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.